Intraperitoneal Meropenem for Polymicrobial Peritoneal Dialysis-Related Peritonitis

Perit Dial Int. 2016;36(5):572-3. doi: 10.3747/pdi.2016.00023.

Abstract

With the current rise in multiresistant gram-negative bacteria, carbapenems are more frequently used. Surprisingly, limited data exist on the pharmacokinetics of meropenem in peritoneal dialysis (PD)-related peritonitis. We report on the pharmacokinetics of repeated intraperitoneal (IP) meropenem during 21 days as treatment for polymicrobial multiresistent PD-related peritonitis.Our current report supports daily doses of 125 mg/L intraperitoneal meropenem in all bags as an effective and safe modality in the treatment of PD-associated peritonitis with multiresistant microorganisms. No signs of over- or underdosing were found based on serial drug concentration measurements at fixed time points up to 21 days.

Keywords: Carbapenems; PD-related peritonitis; meropenem.

Publication types

  • Case Reports

MeSH terms

  • Aged, 80 and over
  • Anti-Bacterial Agents / pharmacokinetics*
  • Anti-Bacterial Agents / therapeutic use
  • Drug Resistance, Multiple
  • Female
  • Follow-Up Studies
  • Humans
  • Infusions, Parenteral
  • Kidney Failure, Chronic / diagnosis
  • Kidney Failure, Chronic / therapy*
  • Meropenem
  • Patient Safety
  • Peritoneal Dialysis, Continuous Ambulatory / adverse effects*
  • Peritoneal Dialysis, Continuous Ambulatory / methods*
  • Peritonitis / drug therapy*
  • Peritonitis / etiology
  • Peritonitis / microbiology
  • Thienamycins / pharmacokinetics*
  • Thienamycins / therapeutic use
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents
  • Thienamycins
  • Meropenem